Hello, I'm Meera Mohan. I'm of the myeloma faculties at the Medical College of Wisconsin. I would like to highlight one of the works that we presented as an oral abstract at ASH 2022. So we know that we are entering an entomic state of SARS-CoV-2 infection in the United States and worldwide. So as patients with multiple myeloma are increasingly getting transplanted, it's important to know what is the effect of having SARS-CoV-2 infection prior to transplant? How does it affect outcomes in our patients? So we have this large data set of patients that predominantly consisted of myeloma, leukemia, and lymphoma. We looked at outcomes of patients who had SARS-CoV-2 infection going into transplant. Interestingly, we found that patients who were transplanted within the first four weeks of SARS-CoV-2 infection had an adverse outcome. They had a high chance of mortality. In addition, we found that this was true if they had moderate to severe SARS-CoV-2 infection. I think this has important implications for our patients who get transplanted. Myeloma is the most common reason for logistic cell transplant in the United States. So we recommend discussing with your doctor about the optimal timing of transplant and, if possible, delaying it in the setting of moderate to severe acute SARS-CoV-2 infection. Thank you.
HealthTree • December 12, 2022